Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.

This study found that flutamide, finasteride, ketoconazole, and EE-CPA all significantly reduced hirsutism scores, hair diameter, and hair growth rate in women with hirsutism over 12 months.

This study observed that low-dose intrauterine exposure to finasteride alters postnatal prostate development in male and female Mongolian gerbils, showing sex-specific differences in receptor expression and tissue changes.

This case report highlights a persistent gynecomastia in a young man following low-dose finasteride, suggesting that the incidence may be underreported and calls for patient counseling and early intervention.

This study found that low doses of bisphenol A may increase proliferation of the ventral prostate in adult rats by altering the estrogen to androgen ratio and gene expression.

This study suggests that lower-dose ethinyl estradiol formulations and progestin-only contraceptives may offer safer options for managing PCOS in obese women due to minimal metabolic effects.

This review discusses the role of androgens in women's sexual health and highlights the need for further research on androgen replacement therapy to optimize quality of life, but reports no new clinical results.

In this study, a 300 mcg daily testosterone patch significantly increased satisfying sexual episodes and sexual desire in postmenopausal women with hypoactive sexual desire disorder not receiving estrogen, compared to placebo.

This study highlights the importance of clinicians understanding the effects of gender-affirming hormones like testosterone, estrogen, and antiandrogens on hair growth, to effectively diagnose and treat androgenetic alopecia in gender minority patients.

This review examines androgen replacement therapy in women for treating androgen deficiency symptoms and reports no new clinical results, while noting potential safety within a specific dose range.

This case report discusses the diagnostic challenges and management options for three siblings with 46, XY DSD due to type 2 5-α reductase deficiency, highlighting the genetic basis and impact on their quality of life.

The researchers reported that cancer incidences are rising over time in developed countries, with potential carcinogenic drivers including advancing age, estrogen, decreasing vitamin D3, and Human Papillomavirus.

The researchers reported that low-dose methotrexate, in combination with surgical dilatation and local treatments, may improve symptoms in patients with severe stenosing vulvovaginal lichen planus.

This review discusses treatments for female acne, highlighting the effectiveness of low-dose oral contraceptives and noting their similar side effects to placebo; it reports no new clinical results.

This review discusses the causes and management of hirsutism, recommending low-dose oral contraceptives with flutamide over cyproterone-containing preparations, but reports no new clinical findings.

In this study, using a 3D culture model, researchers observed that developmental stage and androgen levels influenced murine follicle growth, which may inform treatment for women with low ovarian reserve but cautions against excessive androgen exposure.

This systematic review found that estrogen deficiency in postmenopausal women leads to structural and symptomatic changes in genital and cutaneous tissues, with local estrogen therapy providing short-term benefits, while evidence for device-based treatments remains limited and requires larger trials.

In this case report, a transgender woman with refractory epilepsy began estrogen therapy for gender-affirming purposes, experiencing stable epilepsy and reduced gender dysphoria through ongoing multidisciplinary care, highlighting the importance of careful management for similar patients.

This study observed that intrauterine and early postnatal exposure to finasteride affected prostatic development in Mongolian gerbils, with significant sex-based differences, particularly higher alterations in female prostates.

Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.

This review examines the role of androgens in cutaneous disorders and the potential therapeutic effects of different oral contraceptives, noting variations in individual responses and the influence of genetic and local factors but reports no new clinical results.

This article discusses solitary hirsutism, emphasizing that treatment is mostly cosmetic unless contraception is also desired, and reports no new clinical results.

This study discusses the use of oral contraceptives as a treatment for hyperandrogenism, showing improvement in hirsutism and acne for many women and possibly providing metabolic benefits with certain formulations.

In this study, treatment targeting the estrogen-androgen balance reduced hair loss in 74 out of 104 women with androgenetic alopecia, with some experiencing hair regrowth.

This article discusses the challenges in diagnosing and treating diffuse hair loss in women and emphasizes the importance of distinguishing between androgenetic alopecia, chronic telogen effluvium, and psychogenic pseudo effluvium, but reports no new clinical results.

This article reviews current osteoporosis treatments, focusing on the potential of selective androgen receptor modulators and other agents to enhance bone formation, but provides no new clinical data.

This review discusses the 2011 publications on the side effects of sex hormones and related compounds, without reporting new clinical results.

This review discusses developments in oral contraceptives, highlighting improved individualization, reduced side effects, and enhanced suitability for various women's health needs, but it reports no new clinical results.

This report describes a 66-year-old woman's diagnosis of porphyria cutanea tarda, suggested by her painless blisters on sun-exposed areas, pink urine, and elevated urinary porphyrins.

This study found that intravaginal testosterone significantly improved sexual satisfaction and reduced dyspareunia in postmenopausal women using aromatase inhibitors, with no effect on urinary incontinence.